Thank you for the question. It's nice to be able to interject here.
I use a two-track model to analyze this question. The first is based on approved vaccines alone, those from Pfizer and Moderna, and that is going to lead us to six million doses by the end of Q1, 20 million does by the end of Q2, and 70 million doses by the end of Q3. It's based on that analysis that we are using the end-of-September deadline. But of course we're going to have, hopefully, additional vaccines coming online; that's the purpose of our diversification approach to vaccine procurement. Once those vaccines come online and the vaccines arrive in Canada, those timelines can, hopefully, be moved up.
Thank you.